Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.86

-2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (9495)	11/17/2003 11:29:35 AM
From: Ian@SI	Read Replies (1) of 52153

Some tables comparing the Macugen data with Visudyne may be found at: qltinc.com Webcast replay discussing the results: qltinc.com Sounds as if some Macugen pts had worse vision to start with (i.e. - less vision to lose); larger lesion sizes (i.e. nearer to endpoint for lesion) than the Visudyne trial participants. More side effects which were more severe were noted in the Macugen trial. As a patient, I wouldn't choose the option of 9 injections annually directly into the eye with Macugen. The alternative is 3 intravenous injections with Visudyne and having a non heat generating red laser shone into the eye 30 minutes later. Nor can I understand why a retinal specialist would choose to offer the higher risk approach when there's no improvement in efficacy. Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next